Patents by Inventor Daniela Stefanie Thommen

Daniela Stefanie Thommen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
    Patent number: 11613587
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: March 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Stefanie Thommen, Jens Schreiner
  • COMBINATION THERAPY OF T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20210087291
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: March 25, 2021
    Inventors: Christian KLEIN, Vaios KARANIKAS, Pablo UMANA, Alfred ZIPPELIUS, Daniela Stefanie THOMMEN, Jens SCHREINER
  • Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
    Patent number: 10781262
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 22, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Stefanie Thommen, Jens Schreiner